Quest Diagnostics Incorporated (DGX)
After hours:
| Previous Close | 139.33 |
| Open | 139.58 |
| Bid | 140.14 x 900 |
| Ask | 140.15 x 1000 |
| Day's Range | 139.39 - 142.06 |
| 52 Week Range | 119.59 - 145.62 |
| Volume | |
| Avg. Volume | 975,377 |
| Market Cap | 15.772B |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | 19.11 |
| EPS (TTM) | 7.43 |
| Earnings Date | Jul 24, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | 3.00 (2.11%) |
| Ex-Dividend Date | Jul 08, 2024 |
| 1y Target Est | 147.07 |
PR NewswireBlood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of the Haystack MRD™ tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted
ACCESSWIRELab Week 2024 - Mimi Perdue-Loan
NORTHAMPTON, MA / ACCESSWIRE / May 29, 2024 / Quest Diagnostics: Quest colleagues from coast-to-coast marked Lab Week 2024 with a week full of activities to celebrate our medical laboratory professionals and pathologists. As part of the celebration, ...
ZacksWhy Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
